New analyses of DUALT trials of Xultophy in Type 2 Diabetes- Novo Nordisk
New analyses of phase IIIa DUALT clinical data show that adults with Type 2 Diabetes treated with Xultophy (IDegLira) from Novo Nordisk, the once-daily single injection combination of Tresiba (insulin degludec) and Victoza (liraglutide), resulted in rapid and substantial improvement in glycaemic control, with a beneficial weight profile, as early as 4 weeks after initiation in both insulin-na�ve and insulin-treated patients compared to its individual components.
Xultophy treated patients also had a greater likelihood of reaching both pre-prandial (before meal) and post-prandial (after meal) blood glucose targets compared with either insulin degludec or liraglutide, suggesting increased predictability with treatment. Data from the 52-week DUALT I and the 26-week DUALT II clinical trials were presented at the 50th European Association for the Study of Diabetes (EASD) annual meeting.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.